2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of test
2016
Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil
Heinrich M, Zembrzuski V, Ota M, Sacchi F, Teixeira R, Acero P, Cunha G, Souza-Santos R, Croda J, Basta P. Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. Tuberculosis 2016, 101: 15-24. PMID: 27865386, DOI: 10.1016/j.tube.2016.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntitubercular AgentsArylamine N-AcetyltransferaseBrazilChemical and Drug Induced Liver InjuryChildChild, PreschoolCross-Sectional StudiesCytochrome P-450 CYP2E1FemaleGenetic Predisposition to DiseaseGenotypeGlutathione TransferaseHumansIncidenceInfantLongitudinal StudiesMaleMiddle AgedPolymorphism, Single NucleotideTuberculosis, PulmonaryYoung AdultConceptsIncidence of hepatotoxicityAdverse drug reactionsIndigenous patientsAnti-TB drug-induced hepatotoxicityNon-conditional logistic regressionClinical-epidemiological factorsClinical-epidemiological variablesNon-Indigenous patientsGenetic polymorphismsRisk of hepatotoxicityDrug-induced hepatotoxicityPolymorphisms of CYP2E1Anti-tuberculosis drugsAcetylation profileTB patientsSerum levelsDrug reactionsGSTM1 polymorphismOdds ratioLiver enzymesNon-Indigenous populationsTherapeutic schemesPharmacogenetic analysisBetter outcomesPatients